Intraoperative Brachytherapy for Central Nervous System Lesions: A Validation Study of a Radioactive Seed Loading Device
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03088579|
Recruitment Status : Unknown
Verified March 2017 by St. Joseph's Hospital and Medical Center, Phoenix.
Recruitment status was: Recruiting
First Posted : March 23, 2017
Last Update Posted : March 23, 2017
|Condition or disease||Intervention/treatment|
|Central Nervous System Lesion||Device: GammaTile seed loader|
This is a 100 patient observational-design study for the purpose of testing the seed loader device as a method of arranging and securing the seeds in a carrier in a set pattern for the convenient use of the neurosurgeon against the backdrop of a hodgepodge of currently available techniques (seed in suture, seed in mesh, loose seeds), all of which currently need to be secondarily secured with some additional, not currently standardized material, in a cumbersome, time-consuming, and not assuredly accurate manner. An additional primary objective will be an assessment of the loader device as a radiation protection tool for the user and staff during seed placement in the carrier and prior to intracranial carrier placement. Secondary objectives will be conformality of pre- and post-implant dosimetry (expected vs achieved) and post implant stability (seed shift) over time as judged on a routine follow up MRI. An additional proposed endpoint is an economic (cost) comparison to other modalities.
Eligible patients are those deemed appropriate for and scheduled to undergo adjuvant brachytherapy of the central nervous system as determined by the radiation oncologist and neurosurgeon. Potential candidates will have a lesion(s) that may be newly diagnosed or recurrent, in need of gross total or near gross total resection, and such that in the opinion of the operating surgeon it would be both amenable to and in need of the proposed treatment. Informed consent will be obtained. Radiation oncologist and neurosurgeon will determine appropriateness of the proposed procedure and the radiation oncologist and neurosurgeon will determine the volume and configuration of the area to be implanted.
A carrier using currently available material (lyophilized bovine-derived collagen, Duraform or similar) stocked in the BNI OR. The isotope (seeds) are also already approved for use anywhere in the body, are in use and on the hospital's radioactive materials license (RML). Patients will have pre- and post-operative computerized tomography (CT) or magnetic resonance imaging (MRI) as routine care, and post-operative CT's as per routine implant case dosimetry. All applicable radiation safety procedures will continue to be followed. The sterilizable loader(s) will be provided as a non-charge-item, and are anticipated to be classified as a "Class 1" device by the FDA as they are not implanted and have no direct patient contact.
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||Intraoperative Brachytherapy for Central Nervous System Lesions: A Validation Study of a Radioactive Seed Loading Device|
|Actual Study Start Date :||April 2, 2013|
|Estimated Primary Completion Date :||March 1, 2018|
|Estimated Study Completion Date :||June 1, 2018|
- Device: GammaTile seed loader
Patients are chosen based on symptomatic tumor/radiographic finding of a surgically accessible mass. Surgery will be done in usual fashion. A cavity will be left where the tumor was. Size of operative bed will be measured using a surgical dissector and standard operating room ruler. A sheet of surgical fabric may be used to estimate size of cavity. If pathology is positive the study treatment will continue. If not, patient will not be on trial. If patient is eligible, radiation oncologist will form custom implants using a seed(s) of Cesium-131, with other biocompatible materials used to achieve maximum dosimetric conformality. Surgeon will place constructs into cavity until the operative bed is fully addressed. Implant is not expected to migrate. Surgicel, bioglue or similar material may be used to secure seeds. Wound will be closed in standard fashion. The last 10 patients will be asked to participate in an effort to gauge costs related to radiation portion of treatment.
- User's Experience [ Time Frame: Immediately post-operatively ]Analyze users' (radiation oncologists and neurosurgeons) experience with the loader methodology by utilizing a standardized questionnaire recording 1) time added to case, 2) the size and size range of implants utilized, 3) conformality to operative bed, and 4) ease of use. Both perceptual (subjective) and numerical (objective) data will be obtained.
- Shielding [ Time Frame: Immediately post-operatively ]Evaluate shielding (radiation protection ability) of shielded loader through mRm measurements while seeds are in loader prior to implantation: surface of loader (mRm/hour), at 1 meter (mRm/hour), and at 3 meter (mRm/hour).
- Post-Implant Dosimetric Analysis [ Time Frame: Post-operative Day 1 ]Using Advisory Committee on the Medical Uses of Isotopes (ACMUI) guidelines, analyze the post-implant dosimetry and compare with the pre-plan dosimetry (expected vs achieved dosimetry) both of which are standard procedures for brachytherapy.
- Seed Migration [ Time Frame: Post-operative Day 1 ]Presence or absence of source (seed) migration on subsequent scans ordered for routine follow-up.
- Economic Impact [ Time Frame: Post-Operative Day 1, at follow-up per routine care (up to 5 years) ]For all study patients obtain sufficiently detailed, global costs for treatment to be able to analyze the overall cost of this modality compared to existing literature data for other forms of adjuvant therapies where available.
- Progression Free Survival (PFS) [ Time Frame: Pre-Operative and at follow-up per routine care (up to 5 year) ]The length of time during and after treatment that the participant lives with the disease but it does not get worse.
- Overall Survival (OS) [ Time Frame: Pre-Operative and at follow-up per routine care (up to 5 year) ]The length of time from when consent is signed that participants are still alive.
- Zubrod Performance Scale [ Time Frame: Pre-Operative, Post-Operative Day 1, at follow-up per routine care (up to 5 years) ]
Participants ability to carry out activities of daily living will be scored per the following scale:
0 Fully active, able to carry on all predisease activities without restriction (Karnofsky 90-100);
- Restricted in physically strenuous activity but ambulatory and able to carry work of a light or sedentary nature. For example, light housework, office work (Karnofsky 70-80);
- Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours (Karnofsky 50-60);
- Capable of only limited self-care, confined to bed or chair 50% or more of waking hours (Karnofsky 30-40);
- Completely disabled. Cannot carry on self-care. Totally confined to bed or (Karnofsky 10-20);
- Death (Karnofsky 0).
- Neurologic Function Status Scale [ Time Frame: Pre-Operative, Post-Operative Day 1, at follow-up per routine care (up to 5 years) ]
Participants' neurologic status will be scored per the following scale:
0 No neurologic symptoms - fully active at home/work without assistance;
- Minor neurologic symptoms - fully active at home/work without assistance;
- Moderate neurologic symptoms - fully active at home/work but requires assistance;
- Moderate neurologic symptoms - less than fully active at home/work and requires assistance;
- Severe neurologic symptoms - totally inactive requiring complete assistance at home or in institution--unable to work.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03088579
|Contact: Theresa Thomas, MSemail@example.com|
|United States, Arizona|
|Barrow Brain and Spine||Recruiting|
|Phoenix, Arizona, United States, 85013|
|Contact: Theres Thomas, MS 602-406-7709 Theresa.Thomas@dignityhealth.org|
|Principal Investigator: David G Brachman, MD|
|Sub-Investigator: Peter Nakaji, MD|
|Barrow Neurological Institute at St. Joseph's Hospital and Medical Center||Recruiting|
|Phoenix, Arizona, United States, 85013|
|Study Chair:||David G Brachman, MD||Barrow Neurological Institute|
|Study Chair:||Peter Nakaji, MD||Barrow Neurological Institute|